Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Ientilucci

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
The Prostate|December 8, 2021
Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with syn- or metachronous metastatic diseaseChristopher Ma, Michelle Downes, Rahi Jain, et al.
The Journal of Urology|June 5, 2020
Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?Dominik Deniffel, Emmanuel Salinas, Marc Ientilucci, et al.
The Journal of Urology|September 24, 2020
Reply by AuthorsDominik Deniffel, Emmanuel Salinas, Marc Ientilucci, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
The Prostate|December 8, 2021
Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with syn- or metachronous metastatic diseaseChristopher Ma, Michelle Downes, Rahi Jain, et al.
The Journal of Urology|June 5, 2020
Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?Dominik Deniffel, Emmanuel Salinas, Marc Ientilucci, et al.
The Journal of Urology|September 24, 2020
Reply by AuthorsDominik Deniffel, Emmanuel Salinas, Marc Ientilucci, et al.
Pageof 1